This work could not be checked — none of the deposited references carry a DOI. No claim is made either way
about its reference list.
The 37 references without a DOI — listed, not checked
no DOI — not checkedTargeting PCSK9 for hypercholesterolemia
no DOI — not checkedThe activation and physiological functions of the proprotein convertases
no DOI — not checkedPCSK9: a key modulator of cardiovascular health
no DOI — not checkedDecreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9
no DOI — not checkedAdenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype
no DOI — not checkedMutations in PCSK9 cause autosomal dominant hypercholesterolemia
no DOI — not checkedLow LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9
no DOI — not checkedSequence variations in PCSK9, low LDL, and protection against coronary heart disease
no DOI — not checkedThe secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation
no DOI — not checkedBiology of proprotein convertase subtilisin kexin 9: beyond low-density lipoprotein cholesterol lowering
no DOI — not checkedLow density lipoprotein binding and uptake by human and rat islet beta cells
no DOI — not checkedInsulin-secreting beta-cell dysfunction induced by human lipoproteins
no DOI — not checkedDirect effect of cholesterol on insulin secretion: a novel mechanism for pancreatic beta-cell dysfunction
no DOI — not checkedLow density lipoprotein can cause death of islet beta-cells by its cellular uptake and oxidative modification
no DOI — not checkedPCSK9-deficient mice exhibit impaired glucose tolerance and pancreatic islet abnormalities
no DOI — not checkedVariable effects of gender and western diet on lipid and glucose homeostasis in aged PCSK9-deficient C57BL/6 mice CSK9PC57BL/6
no DOI — not checkedVariation in PCSK9 and HMGCR and risk of cardiovascular disease and diabetes
no DOI — not checkedPCSK9 genetic variants and risk of type 2 diabetes: a Mendelian randomisation study
no DOI — not checkedAssociation between low-density lipoprotein cholesterol-lowering genetic variants and risk of type 2 diabetes: a meta-analysis
no DOI — not checkedAssociation between familial hypercholesterolemia and prevalence of type 2 diabetes mellitus
no DOI — not checkedDietary iron overload induces visceral adipose tissue insulin resistance
no DOI — not checkedCholesterol in islet dysfunction and type 2 diabetes
no DOI — not checkedImpact of perturbed pancreatic beta-cell cholesterol homeostasis on adipose tissue and skeletal muscle metabolism
no DOI — not checkedCholesterol in pancreatic beta-cell death and dysfunction: underlying mechanisms and pathological implications
no DOI — not checkedProprotein convertase subtilisin/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration
no DOI — not checkedPCSK9 is expressed in pancreatic delta-cells and does not alter insulin secretion
no DOI — not checkedMeta-analysis of impact of different types and doses of statins on new-onset diabetes mellitus
no DOI — not checkedBeta-cell ABCA1 influences insulin secretion, glucose homeostasis and response to thiazolidinedione treatment
no DOI — not checkedCholesterol efflux via ATP-binding cassette transporter A1 (ABCA1) and cholesterol uptake via the LDL receptor influences cholesterol-induced impairment of beta cell function in mice
no DOI — not checkedDecreased APOE-containing HDL subfractions and cholesterol efflux capacity of serum in mice lacking Pcsk9
no DOI — not checkedNew developments in proprotein convertase subtilisin-kexin 9's biology and clinical implications
no DOI — not checkedThe proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2
no DOI — not checkedCirculating proprotein convertase subtilisin/kexin 9 (PCSK9) regulates VLDLR protein and triglyceride accumulation in visceral adipose tissue
no DOI — not checkedPCSK9 induces CD36 degradation and affects long-chain fatty acid uptake and triglyceride metabolism in adipocytes and in mouse liver
no DOI — not checkedEvaluation of the efficacy, safety and glycaemic effects of evolocumab (AMG 145) in hypercholesterolaemic patients stratified by glycaemic status and metabolic syndrome
no DOI — not checkedCardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial
no DOI — not checkedProprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) inhibitors and incident type 2 diabetes: a systematic review and meta-analysis with over 96,000 patient-years
checked 2026-07-23 — re-checked daily as this page is visited;
titles and statuses come from Crossref and DataCite and are not part of the signed record
Both snippets point at the live badge image and link back to this page. The
badge re-renders from the daily check, so an embed never goes stale by more than a day of visits.